Efficacy News and Research

RSS

Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy

Larynx cancer patients treated with alternating cycles of chemotherapy and radiation have similar outcomes to patients treated with chemotherapy followed by radiation, according to data from a randomized controlled trial in the January 27 online issue of the Journal of the National Cancer Institute.

29 Jan 2009

Researchers discover link between brain iron levels and serotonin

Vanderbilt University Medical Center investigators have found a surprising link between brain iron levels and serotonin, a neurotransmitter involved in neuropsychiatric conditions ranging from autism to major depression.

29 Jan 2009

Study shows no standardized approach to epidural steroid injections for back pain

Today at the American Academy of Pain Medicine's 25th Annual Meeting, researchers from University of California at San Diego report that no standardized practices exist for administering an epidural steroid injection for back pain. Researchers looked at many factors including: which steroids were given, the amount of steroid used, and whether or not a local anesthetic was mixed with the steroid.

29 Jan 2009

Leconotide, an investigative calcium channel blocker, shows potential as pain treatment

Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

29 Jan 2009

Drug-coated stents less risky for heart bypass patients

Coronary bypass surgery may carry less risk of serious complications if stents coated with a drug that suppresses cell growth are used in the procedure rather than bare-metal stents, UT Southwestern Medical Center researchers and colleagues have found.

23 Jan 2009

Inhaled corticosteroids reduces severity of asthma attacks in preschoolers

The largest study of its kind on preschoolers has demonstrated that preventive treatment with high doses of inhaled corticosteroids is effective in reducing the severity and duration of asthma attacks triggered by colds.

23 Jan 2009

New treatment for latent form of tuberculosis

Patients who are infected with the latent form of tuberculosis (TB) show no symptoms and are not contagious, yet they pose the biggest challenge when it comes to controlling the disease.

23 Jan 2009

Slices of living human brain tissue are helping scientists identify new stroke therapies

Slices of living human brain tissue are helping scientists learn which drugs can block the waves of death that engulf and engorge brain cells following a stroke.

21 Jan 2009

Arpida receives FDA complete response letter for Iclaprim

Arpida Ltd. has announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI).

19 Jan 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

Psychological concerns are greatest barriers to an active lifestyle

The main factors influencing the amount of physical exercise people carry out are their self-perceived ability and the extent of their desire to exercise.

19 Jan 2009

Researchers find novel use for old compound in cancer treatment

The compound, alpha-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models.

19 Jan 2009

Higher mortality among unscreened children

Swedish researchers have previously shown that as maternity ward stays become shorter, more and more newborns leave the hospital with undetected life-threatening congenital heart disease.

19 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

FDA issues final guidance on genetically engineered animal regulation

The U.S. Food and Drug Administration has issued a final guidance for industry on the regulation of genetically engineered (GE) animals under the new animal drug provisions of the Federal Food, Drug and Cosmetic Act (FFDCA).

19 Jan 2009

Depressed adolescents not harmed by being part of placebo group in clinical trial

In a national clinical trial, adolescents with moderate to severe depression first given a placebo treatment and then an antidepressant medication alone or in combination with therapy responded just as well over the long term as participants who received active treatment throughout the study, UT Southwestern Medical Center researchers report.

19 Jan 2009

Cell Therapeutics targeting potential Zevalin label expansion,

In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) reviewed 2009 targeted milestones and 2008 accomplishments.

15 Jan 2009

Algeta completes phase II trial with Alpharadin for treating bone metastases in advanced prostate cancer

Algeta ASA has announced that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).

15 Jan 2009

Advaxis wins European patent case involving Lovaxin-C vaccine

The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.

15 Jan 2009

New folate antagonists selectively target pathway important in rheumatoid arthritis

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis.

13 Jan 2009